Fibroblast Growth Factor 21 in Chronic Hepatitis C: A Potential Non-Invasive Biomarker of Liver Status upon Viral Eradication
Fibroblast growth factor 21 (FGF-21), previously recognized as a marker of liver damage and a potential drug target in non-alcoholic fatty liver disease (NAFLD), has unclear implications in hepatitis C virus (HCV) infections. This study aimed to investigate the relationship between FGF-21 levels and...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/13/11/1119 |
| _version_ | 1827639280111976448 |
|---|---|
| author | Filippo Biagi Francesco Carlomagno Martina Carbone Roberta Veralli Umberto Vespasiani-Gentilucci Elisabetta Riva Silvia Manfrini Dario Tuccinardi Adriano De Santis Lucio Gnessi Mikiko Watanabe |
| author_facet | Filippo Biagi Francesco Carlomagno Martina Carbone Roberta Veralli Umberto Vespasiani-Gentilucci Elisabetta Riva Silvia Manfrini Dario Tuccinardi Adriano De Santis Lucio Gnessi Mikiko Watanabe |
| author_sort | Filippo Biagi |
| collection | DOAJ |
| description | Fibroblast growth factor 21 (FGF-21), previously recognized as a marker of liver damage and a potential drug target in non-alcoholic fatty liver disease (NAFLD), has unclear implications in hepatitis C virus (HCV) infections. This study aimed to investigate the relationship between FGF-21 levels and liver health in patients with HCV undergoing direct-acting antiviral (DAA) treatment. Forty-five patients were assessed for liver stiffness, blood chemistry, and other relevant metrics before and after achieving sustained viral response (SVR), defined as the absence of detectable HCV-RNA after 24 weeks of treatment. Post-treatment, all patients showed a decrease in liver stiffness and improved liver enzyme levels (AST and ALT), alongside an increase in FGF-21 levels. Interestingly, the increase in FGF-21 correlated negatively with liver stiffness but showed no correlation with hepatic steatosis. The observed elevation in FGF-21 levels at SVR following DAA therapy for chronic HCV infection can be attributed to the restoration of hepatic function, including its synthetic capabilities. Specifically, the mitigation of liver fibrosis post-HCV eradication is expected to lead to improvements in liver function, such as enhanced albumin and FGF-21 production. This improvement in synthetic function likely drives the increase in FGF-21 levels, rather than changes in liver fat content. We suggest a potential role of FGF-21 as a marker of fibrosis and hepatic cytotoxicity and as a drug target beyond NAFLD, to be confirmed by additional studies. |
| first_indexed | 2024-03-09T16:37:19Z |
| format | Article |
| id | doaj.art-8f4d3c38c1234e8587961683754eb9ad |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-09T16:37:19Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-8f4d3c38c1234e8587961683754eb9ad2023-11-24T14:55:23ZengMDPI AGMetabolites2218-19892023-10-011311111910.3390/metabo13111119Fibroblast Growth Factor 21 in Chronic Hepatitis C: A Potential Non-Invasive Biomarker of Liver Status upon Viral EradicationFilippo Biagi0Francesco Carlomagno1Martina Carbone2Roberta Veralli3Umberto Vespasiani-Gentilucci4Elisabetta Riva5Silvia Manfrini6Dario Tuccinardi7Adriano De Santis8Lucio Gnessi9Mikiko Watanabe10Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, 00161 Rome, ItalyDepartment of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, 00161 Rome, ItalyDepartment of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, ItalyClinical Laboratory Unit, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, ItalyUnit of Clinical Medicine and Hepatology, Area of Medicine, Campus Bio-Medico University of Rome, 00128 Rome, ItalyUnit of Virology, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, ItalyDepartment of Endocrinology and Diabetes, Campus Bio-Medico University of Rome, 00128 Rome, ItalyDepartment of Endocrinology and Diabetes, Campus Bio-Medico University of Rome, 00128 Rome, ItalyDepartment of Translational and Precision Medicine, Sapienza University of Rome, 00185 Rome, ItalyDepartment of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, 00161 Rome, ItalyDepartment of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, 00161 Rome, ItalyFibroblast growth factor 21 (FGF-21), previously recognized as a marker of liver damage and a potential drug target in non-alcoholic fatty liver disease (NAFLD), has unclear implications in hepatitis C virus (HCV) infections. This study aimed to investigate the relationship between FGF-21 levels and liver health in patients with HCV undergoing direct-acting antiviral (DAA) treatment. Forty-five patients were assessed for liver stiffness, blood chemistry, and other relevant metrics before and after achieving sustained viral response (SVR), defined as the absence of detectable HCV-RNA after 24 weeks of treatment. Post-treatment, all patients showed a decrease in liver stiffness and improved liver enzyme levels (AST and ALT), alongside an increase in FGF-21 levels. Interestingly, the increase in FGF-21 correlated negatively with liver stiffness but showed no correlation with hepatic steatosis. The observed elevation in FGF-21 levels at SVR following DAA therapy for chronic HCV infection can be attributed to the restoration of hepatic function, including its synthetic capabilities. Specifically, the mitigation of liver fibrosis post-HCV eradication is expected to lead to improvements in liver function, such as enhanced albumin and FGF-21 production. This improvement in synthetic function likely drives the increase in FGF-21 levels, rather than changes in liver fat content. We suggest a potential role of FGF-21 as a marker of fibrosis and hepatic cytotoxicity and as a drug target beyond NAFLD, to be confirmed by additional studies.https://www.mdpi.com/2218-1989/13/11/1119cirrhosisDAAsFGF-21HCVNAFLDNASH |
| spellingShingle | Filippo Biagi Francesco Carlomagno Martina Carbone Roberta Veralli Umberto Vespasiani-Gentilucci Elisabetta Riva Silvia Manfrini Dario Tuccinardi Adriano De Santis Lucio Gnessi Mikiko Watanabe Fibroblast Growth Factor 21 in Chronic Hepatitis C: A Potential Non-Invasive Biomarker of Liver Status upon Viral Eradication Metabolites cirrhosis DAAs FGF-21 HCV NAFLD NASH |
| title | Fibroblast Growth Factor 21 in Chronic Hepatitis C: A Potential Non-Invasive Biomarker of Liver Status upon Viral Eradication |
| title_full | Fibroblast Growth Factor 21 in Chronic Hepatitis C: A Potential Non-Invasive Biomarker of Liver Status upon Viral Eradication |
| title_fullStr | Fibroblast Growth Factor 21 in Chronic Hepatitis C: A Potential Non-Invasive Biomarker of Liver Status upon Viral Eradication |
| title_full_unstemmed | Fibroblast Growth Factor 21 in Chronic Hepatitis C: A Potential Non-Invasive Biomarker of Liver Status upon Viral Eradication |
| title_short | Fibroblast Growth Factor 21 in Chronic Hepatitis C: A Potential Non-Invasive Biomarker of Liver Status upon Viral Eradication |
| title_sort | fibroblast growth factor 21 in chronic hepatitis c a potential non invasive biomarker of liver status upon viral eradication |
| topic | cirrhosis DAAs FGF-21 HCV NAFLD NASH |
| url | https://www.mdpi.com/2218-1989/13/11/1119 |
| work_keys_str_mv | AT filippobiagi fibroblastgrowthfactor21inchronichepatitiscapotentialnoninvasivebiomarkerofliverstatusuponviraleradication AT francescocarlomagno fibroblastgrowthfactor21inchronichepatitiscapotentialnoninvasivebiomarkerofliverstatusuponviraleradication AT martinacarbone fibroblastgrowthfactor21inchronichepatitiscapotentialnoninvasivebiomarkerofliverstatusuponviraleradication AT robertaveralli fibroblastgrowthfactor21inchronichepatitiscapotentialnoninvasivebiomarkerofliverstatusuponviraleradication AT umbertovespasianigentilucci fibroblastgrowthfactor21inchronichepatitiscapotentialnoninvasivebiomarkerofliverstatusuponviraleradication AT elisabettariva fibroblastgrowthfactor21inchronichepatitiscapotentialnoninvasivebiomarkerofliverstatusuponviraleradication AT silviamanfrini fibroblastgrowthfactor21inchronichepatitiscapotentialnoninvasivebiomarkerofliverstatusuponviraleradication AT dariotuccinardi fibroblastgrowthfactor21inchronichepatitiscapotentialnoninvasivebiomarkerofliverstatusuponviraleradication AT adrianodesantis fibroblastgrowthfactor21inchronichepatitiscapotentialnoninvasivebiomarkerofliverstatusuponviraleradication AT luciognessi fibroblastgrowthfactor21inchronichepatitiscapotentialnoninvasivebiomarkerofliverstatusuponviraleradication AT mikikowatanabe fibroblastgrowthfactor21inchronichepatitiscapotentialnoninvasivebiomarkerofliverstatusuponviraleradication |